Business Context and Reporting Period
This Form 6-K filing by Fresenius Medical Care AG & Co. KGaA, dated June 18, 2019, discloses a corporate action regarding a share buy-back programme. The notification was issued on June 14, 2019, pursuant to EU Market Abuse Regulation requirements.
Key Financial Metrics
The filing does not provide operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figures disclosed relate to the capital allocation programme:
- Maximum Repurchase Value: Up to 660 million Euro (approximately 745 million U.S. Dollar).
- Maximum Share Count: Up to 12 million ordinary shares.
- Capital Impact: Approximately 3.2% of the company's share capital.
Material Changes
The filing announces the initiation of a new share buy-back programme authorized by the General Meeting on May 12, 2016. This represents a material change in capital structure strategy, as the repurchased shares will be cancelled to reduce registered share capital.
Guidance, Outlook, and Risks
Programme Terms:
- Duration: June 17, 2019, to June 17, 2020.
- Execution: Shares will be repurchased via the XETRA trading system and/or selected multilateral trading facilities (MTF).
- Pricing Constraints: The purchase price must not deviate by more than 10% from the market price determined by the opening auction on the trading day. Additionally, purchases cannot exceed the higher of the last independent trade price or the highest current independent purchase bid.
- Volume Limits: Purchases are capped at 25% of the average daily volume (based on the preceding 20 trading days).
Management Commentary: The programme will be executed by an independent credit institution to ensure compliance with regulatory safe harbour provisions. The company reserves the right to suspend or reinstate the programme at any time.
Risks and Contingencies: The filing does not explicitly list new risks, though the programme is subject to legal permissions and market conditions.
Investor Verification Checklist
- Verify the current market price of Fresenius Medical Care shares against the 10% deviation limit for buy-back execution.
- Monitor the company's website (Investors section) for transaction disclosures, which must be published within seven trading days of execution.
- Confirm the total number of shares repurchased and the final reduction in registered share capital upon programme completion.
- Review the company's liquidity position to ensure the 660 million Euro commitment does not impact operational cash flow.